| Employment |
| No Relationships to Disclose |
|
|
| Leadership |
| No Relationships to Disclose |
|
|
| Stock and Other Ownership Interests |
| Company: Actym Therapeutics |
| Recipient: You |
| Company: Mavu Pharmaceutical |
| Recipient: You |
| Company: Pyxis |
| Recipient: You |
| Company: Alphamab Oncology |
| Recipient: You |
| Company: Tempest Therapeutics |
| Recipient: You |
| Company: Kanaph Therapeutics |
| Recipient: You |
| Company: Onc.AI |
| Recipient: You |
| Company: Arch Oncology |
| Recipient: You |
| Company: Stipe |
| Recipient: You |
| Company: NeoTX |
| Recipient: You |
| Company: NeoTX |
| Recipient: You |
|
| Honoraria |
| No Relationships to Disclose |
|
|
| Consulting or Advisory Role |
| Company: Bristol-Myers Squibb |
| Recipient: You |
| Company: Merck |
| Recipient: You |
| Company: EMD Serono |
| Recipient: You |
| Company: Novartis |
| Recipient: You |
| Company: 7 Hills Pharma |
| Recipient: You |
| Company: Janssen |
| Recipient: You |
| Company: Reflexion Medical |
| Recipient: You |
| Company: Tempest Therapeutics |
| Recipient: You |
| Company: Alphamab Oncology |
| Recipient: You |
| Company: Abbvie |
| Recipient: You |
| Company: Bayer |
| Recipient: You |
| Company: Incyte |
| Recipient: You |
| Company: Partner Therapeutics |
| Recipient: You |
| Company: Synlogic |
| Recipient: You |
| Company: Werewolf |
| Recipient: You |
| Company: Ribon Therapeutics |
| Recipient: You |
| Company: Checkmate Pharmaceuticals |
| Recipient: You |
| Company: CStone Pharmaceuticals |
| Recipient: You |
| Company: Nektar |
| Recipient: You |
| Company: Regeneron |
| Recipient: You |
| Company: Rubius |
| Recipient: You |
| Company: Tesaro |
| Recipient: You |
| Company: Xilio |
| Recipient: You |
| Company: Xencor |
| Recipient: You |
| Company: Alnylam |
| Recipient: You |
| Company: Crown Bioscience |
| Recipient: You |
| Company: Flame Biosciences |
| Recipient: You |
| Company: Genentech |
| Recipient: You |
| Company: Kadmon |
| Recipient: You |
| Company: KSQ Therapeutics |
| Recipient: You |
| Company: Immunocore |
| Recipient: You |
| Company: Inzen |
| Recipient: You |
| Company: Pfizer |
| Recipient: You |
| Company: Silicon Therapeutics |
| Recipient: You |
| Company: TRex Bio |
| Recipient: You |
| Company: Bright Peak |
| Recipient: You |
| Company: Onc.AI |
| Recipient: You |
| Company: STipe |
| Recipient: You |
| Company: Codiak Biosciences |
| Recipient: You |
| Company: Day One Therapeutics |
| Recipient: You |
| Company: Endeavor |
| Recipient: You |
| Company: Gilead Sciences |
| Recipient: You |
| Company: Hotspot Therapeutics |
| Recipient: You |
| Company: SERVIER |
| Recipient: You |
| Company: STINGthera |
| Recipient: You |
| Company: Synthekine |
| Recipient: You |
|
| Speakers' Bureau |
| No Relationships to Disclose |
|
|
| Research Funding |
| Company: Merck |
| Recipient: Your Institution |
| Company: Bristol-Myers Squibb |
| Recipient: Your Institution |
| Company: Incyte |
| Recipient: Your Institution |
| Company: Corvus Pharmaceuticals |
| Recipient: Your Institution |
| Company: Abbvie |
| Recipient: Your Institution |
| Company: Macrogenics |
| Recipient: Your Institution |
| Company: Xencor |
| Recipient: Your Institution |
| Company: Array BioPharma |
| Recipient: Your Institution |
| Company: Agios |
| Recipient: Your Institution |
| Company: Astellas Pharma |
| Recipient: Your Institution |
| Company: EMD Serono |
| Recipient: Your Institution |
| Company: Immatics |
| Recipient: Your Institution |
| Company: Kadmon |
| Recipient: Your Institution |
| Company: Moderna Therapeutics |
| Recipient: Your Institution |
| Company: Nektar |
| Recipient: Your Institution |
| Company: Spring bank |
| Recipient: Your Institution |
| Company: Trishula |
| Recipient: Your Institution |
| Company: KAHR Medical |
| Recipient: Your Institution |
| Company: Fstar |
| Recipient: Your Institution |
| Company: Genmab |
| Recipient: Your Institution |
| Company: Ikena Oncology |
| Recipient: Your Institution |
| Company: Numab |
| Recipient: Your Institution |
| Company: Replimmune |
| Recipient: Your Institution |
| Company: Rubius Therapeutics |
| Recipient: Your Institution |
| Company: Synlogic |
| Recipient: Your Institution |
| Company: Takeda |
| Recipient: Your Institution |
| Company: Tizona Therapeutics, Inc. |
| Recipient: Your Institution |
| Company: BioNTech AG |
| Recipient: Your Institution |
| Company: Scholar Rock |
| Recipient: Your Institution |
| Company: Next Cure |
| Recipient: Your Institution |
|
| Patents, Royalties, Other Intellectual Property |
| Please describe: Serial #15/612,657 (Cancer Immunotherapy), |
| Recipient: You |
| Please describe: Serial #PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof)
|
| Recipient: You |
|
| Expert Testimony |
| No Relationships to Disclose |
|
|
| Travel, Accommodations, Expenses |
| Company: Bristol-Myers Squibb |
| Recipient: You |
| Company: Array BioPharma |
| Recipient: You |
| Company: EMD Serono |
| Recipient: You |
| Company: Janssen |
| Recipient: You |
| Company: Merck |
| Recipient: You |
| Company: Novartis |
| Recipient: You |
| Company: Reflexion Medical |
| Recipient: You |
| Company: Mersana |
| Recipient: You |
| Company: Pyxis |
| Recipient: You |
| Company: Xilio |
| Recipient: You |
|
| Other Relationship |
| No Relationships to Disclose |
|
|
| (OPTIONAL) Uncompensated Relationships |
| not answered |
|
|
| (OPTIONAL) Open Payments Link |
| not answered |
|
|